Wir verwenden Cookies, um Ihre Nutzer-Erfahrung zu verbessern. Um die neuen Datenschutzrichtlinien zu erfüllen, müssen wir Sie nach Ihrer Zustimmung für Cookies fragen. Weitere Informationen
Publikationen
Wirkungen von NADH
Stickstoffmonoxid (NO) und seine Wirkungen an Auge, Herz, Hirn und LungeUniv.Prof. Dr.Dr. Joerg George Birkmayer Nutrition Press Magazine, Aug 2019, p. 33-35 |
NADH-supplementation decreased pinacidil-primed I K(ATP) in ventricular cardiomyocytes by increasing intracellular ATPPelzmann B, Hallström S, Schaffer P, Lang P, Nadlinger K, Birkmayer GD, Vrecko C, Reibnegger G and Koidl B. Brit. J. Pharm. 2003 139, 749-754. |
The Reduced Coenzyme Nicotinamide Adenine Dinucleotide (NADH) repairs DNA damage of PC12 cells induced by doxorubicinZhang JR, Vrecko K, Nadlinger K, Storga D, Birkmayer GD, Reibnegger G J. Tumor Marker Oncol. 1998; 13, 5-17. |
X-ray induced LO2 cells damage rescued by new antioxidant NADHFa-Quan L, Zhang JR. World J. Gastorenterol. 2003, 9(8): 1781-1785. |
The Reduced Coenzyme Nicotinamide Adenine Dinucleotide (NADH) rescues PC 12 cells from ApoptosisZhang JR, Vrecko K, Nadlinger K. Storga D. Birkmayer GD, Reibnegger G J. Tumor Marker Oncol. 1998; 13(3): 11-24. |
The Cytoprotection of Nicotinamide Adenine Dinucleotide (NADH) by the Mitochondrial Regulation MechanismMeng Xu, Hang JR, Hui SSC J. Tumor Marker Oncol. 1998; 17: 167 - 174. |
The reduced coenzyme Nicotinamide Adenine Dinucleotide (NADH) prevent hepatic cells from ApoptosisMeng Xu, Jiren Zhang Int. Journal of Modern Cancer Therapy 2000: 3, 38 - 41. |
The antioxidative capacity of ENADA®-NADH in humansReibnegger G, Greilberger J, Juergens G. and Oettl K. J. Tumor Marker Oncol. 2003; 18, 37-41. |
Oral NADH effects blood pressure, lipid peroxidation and lipid profile in spontaneously hypertensive ratsBusheri N, Taylor J, Lieberman S, Mirdamadi-Zonosi N, Birkmayer G, Preuss HG Geriat. Nephrol. Urol. 1998; 18(2) 95-100. |
Influence of reduced Nicotinamide Adenine Dinucleotide (NADH) on the production of Interleukin-6 by peripheral human blood leucocytesNadlinger K, Birkmayer J, Gebauer F, Kunze R Neuroimmunomodulation, 2002; 9: 203-208. |
NADH stimulates endogenous dopamine biosynthesis by enhancing the recycling of tetrahydrobiopterin in rat phaechromocytoma cellsVrecko K, Storga D, Birkmayer GD, Möller R, Tarfeit E, Horejsi R, Reibnegger G Biochimica et Biophysica Acta 1997; 1361: 59-65. |
Effects of acute and chronic NADH Administration on Peripheral and Central Norepinenphrine and Dopamine Synthesis in the RatGardier AM Birkmayer Institute for Parkinson Therapy, Internal Lab Report No. 94070401. |
NADH: Sensor of blood flow in brain, muscle and other tissuesIdo Y., Chang K., Woosley TA, Willimanson JR FASEB, 2001; 15: 1419- 1421. |
Reduced nicotinamide nucleotides prevent nitration of tyrosine hydroxylase by peroxinitriteKuhn DM, Geddes TJ. Brain Research 2002; 933: 85-89. |
NAD+ dependent repair of damaged DNA by human cell extractsSatoh MS, Pirier GG, Lindahl T. Biol. Chem. 1993; 268; 8: 5480-5487. |
Stabilität, Bioverfügbarkeit und Sicherheit von NADH
Stable, ingestable and absorbable NADH and NADPH therapeutic compositionsBirkmayer JGD. United States Patent No. 5.332.727, 1994. |
Stable, ingestable and absorbable NADH and NADPH therapeutic compositionsBirkmayer JGD. European Patent EP 0 697859, 1995. |
Investigational New drug Application Birmadil™ Tablets 5mg containing reduced ß-nicotinamide adeninie dinucleotide for Treatment of Dementia of the Alzheimer’s TypeBirkmayer Pharmaceuticals IND Number 49,766 1996. |
Bioavailability of reduced nicotinamide-adenine-dinucleotide (NADH) in the central nervous system of the anaethesized rat measured by laser-induced fluorescence spectroscopyRex A, Hentschke MP, Fink H Pharmacol. Toxicol. 2002; 90: 220-228. |
Zur Entwicklung von stabilen Arzneiformen des Coenzyms NADH für die perorale und parenterale ApplikationMattern C. Ph.D. Dissertation Humboldt Universität, Berlin, 1996. |
Untersuchungen zur Pharmakokinetik von NADH in vivo und in vitroKappes K. Digitale Dissertation, FU Berlin 2005. ISBN 3-886664-054-4. |
On the Safety of Reduced Nicotinamide Adenine Nucleotide (NADH)Birkmayer JGD, Nadlinger K, Hallström S. Journal Environmental Pathology, Toxicology and Oncology 2004; 23: 179-194. |
Safety of stabilized, orally absorbable, reduced nicotinamide adenine dinucleotide (NADH): A 26-week oral tablet administration of ENADA®/NADH for chronic toxicity study in ratsBirkmayer JGD, Nadlinger K. Drugs experimental clinical Research 2002; 28: 185-182. |
Anwendungsbereiche und Wirkungen von NADH>
Diabetes
Metabolic and Anthropometric Effects of NADH RAPID Energy in Diabetic Type 2Rahal Lotfi, Joerg George Birkmayer, Ahmed Ghouni Journal of Food Science and Engineering 6 (2016) 280-285 |
Parkinson Krankheit
Nicotinamide adenine dinucleotide (NADH) - a new therapeutic approach to Parkinson’s disease: Comparison of oral and parenteral applicationBirkmayer JGD, Vrecko C, Volc D, Birkmayer W Acta Neurol Scand. 1993; 87: 32-35. |
Stimulation of the endogenous L-dopa biosynthesis - a new principle for the therapy of Parkinson’s disease: the clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH)Birkmayer JGD, Birkmayer W. Acta Neurol Scan. 1989; 126:183-187. |
Stimulation of dopamine biosynthesis in culture PC12 pheochromocytoma cells by the coenzyme nicotinamide adenine dinucleotide (NADH)Vrecko K, Birkmayer JGD, Krainz J. J.Neural.Transm. 1993; 5: 147-156. |
Depression
The reduced nicotinamide adenine dinucleotide (NADH) as biological antidepressive agent. Experience with 205 patientsBirkmayer JGD, Birkmayer W New trends in Clinical Neuropharmacology 1991; 5: 75-86. |
Antidepressant-like effect of nicotinamide adenine dinucleotide in the forced swim test in ratsRex A, Schickert R, Fink H Pharmacology, Biochemistry and Behaviour 2004; 77: 303-307. |
Chronische Müdigkeit
The therapeutic effect of NADH in patients with Chronic Fatigue SyndromeForsyth L, Preuss. H, Carneiro ML, Chiazze R, Birkmayer GD, Bellanti J Ann. Allergy Asthma and Immunol., 199.9; 82: 185-191. |
Functional Herbal Medicines & Dietary SupplementsMertens G Nicholas Hall & Company, 2000; S.17-23. |
Die Wirkung von oralem NADH bei Symptomen des Chronischen MüdigkeitssyndromsBirkmayer JGD Journal Orthomolekulare Medizin, 1999; 2: 107-116. |
NADH improves symptoms of patients with chronic fatigue syndromeBirkmayer JGD The Original Internist; 1999; 6: 6-8. |
Alzheimer Krankheit
Treatment of Alzheimer’s Disease with stabilized oral Nicotinamide Adenine Dinucleotide: A randomized, double-blind studyDemarin V, Podobnik-Sarkanji S, Storga-Tomic D, Kay G Drugs exptl. Clin.Res. 2004; 30: 327-337. |
ENADA/NADH improves cognitive impairment of Alzheimer patientsDemarin V, Podobnik-Sarkanji S, Storga-Tomic D, Kay G, Martinic-Popovic,M. Puretic B., Birkmayer JGD J. Tumor Marker Oncology 2003; 18:43-49. |
Improvement of Verbal Fluency in Alzheimer’s Disease After NADH TreatmentDemarin V, Storga-Tomic D, Bosnar-Puretic M, Martinic-Popovic I, Birkmayer J Proceedings 7th Congress European Society for Clinical Neuropharmacology ed: Medimond 2004; 41-45. |
Krebs
NADH in Cancer Prevention and TherapyBirkmayer JGD, Zhang JR, ed. Bagchi D, Preuss H CRC Press 2005; chapter 33, 541- 554. |
Coenzym-1 (NADH) ein wirkungsvolles KrebstherapeutikumUniv.Prof. Dr.Dr. Joerg George Birkmayer Praxismagazin 11/2014 |
Körperliche und geistige Leistung
Einfluss einer NADH Supplementation auf die muskuläre Energiebereitstellung beim Menschen (Influence of NADH supplementation for the muscular energy supply in humans)Grathwohl D, Klann M, Müller HM, Schlachter H, Berg A. Deutsche Zeitschrift für Sportmedizin, 11/2000. |
ENADAlert® improves physical and mental performance in highly conditioned athletesBirkmayer GD, Nadlinger K. J. Tum. Marker Oncol. 2003; 18: 51-55. |
Extracellular metabolization of NADH by blood cells correlated with intracellular ATP levelsNadlinger K, Westerthaler W, Storga-Tomic D, Birkmayer JGD Biophys. Biochim Acta 2002; 1573: 177-182.
Jet Lag und Schlafdefizit
|
